Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Assets (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Non-Current Assets of $4.3 million for Q1 2026, up 14.16% year-over-year from $3.7 million in Q1 2025, and down 17.59% quarter-over-quarter from $5.2 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Assets (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Non-Current Assets history runs 14 years deep, the most recent figure standing at $4.3 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 14.16% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $18.3 million (up 12.51% YoY), while the FY2025 annual figure was $5.2 million, up 31.53% from the prior year.
- Non-Current Assets for Q1 2026 stood at $4.3 million, down from $5.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $5.2 million in Q3 2025, with the low at $3.2 million in Q3 2022.
- The 5-year median for Non-Current Assets is $3.9 million (2023), against an average of $4.2 million.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets jumped 190.91% in 2022, then dropped 22.14% in 2024.
- Viridian Therapeutics, Inc.\DE's Non-Current Assets stood at $3.9 million in 2022, then climbed by 0.71% to $3.9 million in 2023, then decreased by 0.1% to $3.9 million in 2024, then soared by 31.53% to $5.2 million in 2025, then dropped by 17.59% to $4.3 million in 2026.
- Business Quant data shows VRDN's Non-Current Assets at $4.3 million in Q1 2026, $5.2 million in Q4 2025, and $5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 15.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.96 Mn |
| Mar 31, 2026 | 4.27 Mn |
| Dec 31, 2025 | 5.19 Mn |
| Sep 30, 2025 | 5.23 Mn |
| Jun 30, 2025 | 3.57 Mn |
| Mar 31, 2025 | 3.74 Mn |
| Dec 31, 2024 | 3.94 Mn |
| Sep 30, 2024 | 4.54 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Mar 31, 2024 | 3.56 Mn |
| Dec 31, 2023 | 3.95 Mn |
| Sep 30, 2023 | 4.92 Mn |
| Jun 30, 2023 | 5.14 Mn |
| Mar 31, 2023 | 4.04 Mn |
| Dec 31, 2022 | 3.92 Mn |
| Sep 30, 2022 | 3.23 Mn |
| Jun 30, 2022 | 3.66 Mn |
| Mar 31, 2022 | 3.78 Mn |
| Dec 31, 2021 | 3.55 Mn |
| Sep 30, 2021 | 3.27 Mn |